Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2247-2253

  Schellong, G ^a   Riepenhausen, M ^a   Creutzig, U ^a   Ritter, J ^a   Harbott, J ^a   Mann, G ^a   Gadner, H ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; FEMALE; HODGKIN DISEASE; HUMAN; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT PLANNING;

EID: 0030991544     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2247     Document Type: Article

References (55)

1. Arsenau JC, Sponzo RW, Levin DL, et al: Nonlymphomatous malignant tumors complicating Hodgkin's disease: Possible association with intensive therapy. N Engl J Med 287:1119-1122, 1972
2. Canellos GP, De Vita VT, Arseneau JC, et al: Second malignancies complicating Hodgkin's disease in remission. Lancet 1:947-949, 1975
3. Cadman EC, Capizzi RL, Bertino JR: Acute non-lymphocytic leukemia. A delayed complication of Hodgkin's disease therapy: Analysis of 109 cases. Cancer 40:1280-1296, 1977
4. Coleman CN, Williams CJ, Flint A, et al: Hematologic neoplasias in patients treated for Hodgkin's disease. N Engl J Med 297:1249-1252, 1977
5. Valagussa P, Santoro A, Kenda R, et al: Second malignancies in Hodgkin's disease: A complication of certain forms of treatment. Br Med J 280:216-219, 1980
6. Pedersen-Bjergaard J, Larsen SO: Incidence of acute non-lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 16:966-971, 1982
7. Aisenberg AC: Acute nonlymphocytic leukemia after treatment for Hodgkin's disease. Am J Med 75:449-454, 1983
8. Tester WJ, Kinsella TJ, Waller B, et al: Second malignant neoplasms complicating Hodgkin's disease: The National Cancer Institute experience. J Clin Oncol 2:762-769, 1984
9. Valagussa P, Santoro A, Fossati-Bellani F, et al: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830-837, 1986
10. Pedersen-Bjergaard J, Larsen SO, Struck J, et al: Risk of therapy-related leukemia and preleukemia after Hodgkin's disease. Lancet 2:83-88, 1987
11. Van der Velden JW, van Putten WLJ, Guinee VF, et al: Subsequent development of acute nonlymphatic leukemia in patients treated for Hodgkin's disease. Int J Cancer 42:252-255, 1988
12. Henry-Amar M, Pellae-Cosset B, Bayle-Weisgerber C, et al: Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: The Institut Gustave Roussy experience. Recent Results Cancer Res 117:270-283, 1989
13. Kaldor JM, Day NE, Clarke EA, et al: Leukemia following Hodgkin's disease. N Engl J Med 322:7-13, 1990
14. Van Leeuwen FE, Klokman VJ, Habenbeek A, et al: Second cancer risk following Hodgkin's disease: A 20-year follow up study. J Clin Oncol 12:312-325, 1994
15. Van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, et al: Leukemia risk following Hodgkins' disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, numbers of episodes of chemotherapy and bone marrow damage. J Clin Oncol 12:1063-1073, 1994
16. Valagussa PA, Bonadonna G: Carcinogenic effects of cancer treatment, in Peckham M, Pinedo H, Veonesi U (eds): Oxford Textbook of Oncology, vol 2. Oxford, United Kingdom, Oxford University, 1995, pp 2348-2358
17. Boivin JF, Hutchinson GB, Lyden M, et al: Second primary cancers following treatment of Hodgkin's disease. J Natl Cancer Inst 72:233-241, 1984
18. Sullivan MP, Ramirez I, Ried HL: Second malignancies following Hodgkin's disease in children differ from those of adults: Incidence occurring among 228 pediatric HD patients. Proc Am Assoc Cancer Res 24:160, 1983 (abstr)
19. Meadows AT, Obringer AC, Marrero O, et al: Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factors. Med Pediatr Oncol 17:477-484, 1989
20. Bhatia S, Robinson L, Oberlin O, et al: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 12:745-751, 1996
21. Tucker MA, Coleman CN, Cox RS, et al: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76-81, 1988
22. Colman M, Easton DF, Horwich A, et al: Second malignancies and Hodgkins's disease - The Royal Marsden Hospital experience. Radiother Oncol 11:229-238, 1988
23. Van Leeuwen FE: Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillière's Clin Haematol 9:57-85, 1996
24. Tucker MA, Meadows AT, Boice JD, et al: Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78:459-464, 1987
25. Kuschner BH, Zauber A, Tan CTC: Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. Cancer 62:1364-1370, 1988
26. Schellong G, Strauch S, Waubke AK, et al: Combined modality treatment with reduced chemotherapy and radiotherapy, and selective splenectomy, in children with Hodgkin's disease, in Cavalli F, Bonadonna G, Rozencweig M (eds): Malignant Lymphomas and Hodgkin's Disease: Experimental and Therapeutic Advances. The Hague, The Netherlands, Martinus Nijhoff, 1985, pp 617-626
27. Schellong G: The German cooperative therapy studies. An approach to minimize treatment modalities and invasive staging procedures, in Kamps WA (ed): Hodgkin's Disease in Children. Boston, MA, Kluwer Academic, 1988, pp 277-289
28. Brämswig J, Hörnig-Franz I, Riepenhausen M, et al: The challenge of pediatric Hodgkin's Disease - Where is the balance between cure and long-term toxicity? A report of the West German multicenter studies DAL-HD-78, DAL-HD-82, and DAL-HD-85. Leuk Lymph 2:183-193, 1990
29. Schellong G, Hörnig-Franz I, Rath B, et al: Reduction of radiation dosage to 20-30 Gy in the frame-work of a combined chemo-/radiotherapy in childhood Hodgkin's disease - A report of the cooperative therapy study DAL-HD-87. Klin Pädiatr 206:253-262, 1994
30. Schellong G, Hörnig-Franz I: Salvage therapy in childhood Hodgkin's disease, in Zander AR, Barlogie B (eds): Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's-Lymphoma and Multiple Myeloma. Berlin, Germany, Springer Verlag, 1993, pp 8-10
31. Schellong G, Waubke-Landwehr AK, Langermann HJ, et al: Prediction of splenic involvement in children with Hodgkin's disease. Significance of clinical and intra-operative findings. A retrospective statistical analysis of 154 patients in the German therapy study DAL-HD-78. Cancer 57:2049-2056, 1986
32. Vandenbroucke JP: A shortcut method for calculating the 95 per cent confidence interval of the standardized mortality ratio. Am J Epidemiol 115:303-304, 1982
33. Kaatsch P, Haaf HG, Michaelis J: Jahresbericht 1993 des Deutschen Kinderkrebsregisters. Mainz, Germany, Johann-Gutenberg-Universitåt, 1994
34. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1968
35. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, Wiley, 1980
36. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:63-170, 1966
37. Jenkin D, Greenberg M, Fitzgerald A: Second malignant tumors in childhood Hodgkin's disease. Med Pediatr Oncol 26:373-379, 1996
38. Blayney DW, Longo DL, Young RC, et al: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 316:710-714, 1987
39. Pedersen-Bjeergaard J, Philip P, Larsen SO, et al: Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083-1091, 1990
40. Sandoval C, Pui C-H, Bowman LC, et al: Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol 11:1039-1045, 1993
41. Pedersen-Bjergaard J, Philip P, Larsen SO, et al: Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia 7:1039-1986, 1993
42. Lennard A, Jackson GH, Carey PJ, et al: Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease: Case report and review of the literature. Leukemia 5:624-627, 1991
43. Cortes J, O'Brien S, Kantarjian H, et al: Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia 8:2174-2178, 1994
44. Rubin CM, Arthur DC, Woods WG, et al: Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy. Blood 78:2982-2988, 1991
45. Aventin A, Brunet S, De Andres L, et al: Translocation (3:21) in a patient with secondary hematological malignancy. Cancer Genet Cytogenet 50:227-229, 1990
46. Pedersen-Bjergaard J, Philip P: Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 78:1147-1148, 1991
47. Larson RA, Le Beau MM, Ratain MJ, et al: Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood 79:1892-1893, 1992
48. Robison LL: Methodologie issues in the study of second malignant neoplasms and pregnancy outcomes. Med Pediatr Oncol 1:41-44, 1996 (suppl)
49. Hoppe RT: Secondary leukemia and myelodysplastic syndrome after treatment for Hodgkin's disease. Leukemia 6:155-157, 1992 (suppl 4)
50. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al: Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 304:1137-1143, 1992
51. Van Leeuwen FE, Somers R, Hart AAM: Splenectomy in Hodgkin's disease and second leukemias. Lancet 2:210-211, 1987
52. Tura S, Fiacchini M, Zinzani PL, et al: Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 11:925-930, 1993
53. Nelson DF, Cooper S, Weston MG, et al: Second malignant neoplasms in patients treated for Hodgkin's disease with radiotherapy or radiotherapy and chemotherapy. Cancer 48:2386-2393, 1981
54. Beatty O III, Hudson MM, Greenwald C, et al: Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 13:603-609, 1995
55. Schellong G: The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study Group. Ann Oncol 7:67-72, 1996 (suppl 4)